Illustrating human PLD.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Coupling Lipid Nanoparticle Structure and Automated Single-Particle Composition Analysis to Design Phospholipase-Responsive Nanocarriers.Advanced materials (Deerfield Beach, Fla.) · 2022
   Article
2. PLD1 promotes reactive oxygen species production in vascular smooth muscle cells and injury-induced neointima formation.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2022
   Article

Corrections and comments

• Comment on
  Human PLD structures enable drug design and characterization of isoenzyme selectivity.2020
• Comment on
  Crystal structure of human PLD1 provides insight into activation by PI(4,5)P2020
• Erratum issued
  Author Correction: Illustrating human PLD.2020

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as